A “stealth pharma,” according to the folks at Pharmaceutical Executive, is any drug company that’s not a Big Pharma. In other words, it’s grab-bag of outfits that includes everything from specialty pharmas hawking retread drugs to biotechs to generics makers. Which, of course, makes them difficult to characterize. So it’s fascinating to seeĀ Bill Trombetta, a...
Pharma Industry Archive
June 2008
Given the challenges facing Big Pharma — expiring patents, waning drug pipelines, the imploding blockbuster model, and increasing political pressure on its marketing practices — it’s hard not to wonder sometimes just who in their right minds would want to lead its giant but fragile companies over the next decade or two. Pharmaceutical Executive has an answer in its recent...
So Pfizer apparently won’t be playing the spoiler in the Daiichi-Ranbaxy merger after all. Instead, CEO Jeff Kindler cut a deal with the Indian generics maker that will delay the introduction of generic Lipitor by about 20 months. Ranbaxy is now spared the cost and uncertainty involved in continuing to batter down Pfizer’s patent defenses, while Pfizer is guaranteed an additional...
The saga of Avastin and Lucentis — two Genentech drugs used to treat a blinding condition called age-related macular degeneration, even though one is about 50 times cheaper than the other — is one of those stories that just gets better the longer it goes on. A quick recap: Avastin, a cancer drug, is biochemically very similar to Lucentis, which Genentech specifically developed to...
Much as I suspected when I first wrote about Pfizer’s attempts to minimize potentially serious neurological side effects of its smoking-cessation drug Chantix, the drugmaker’s stonewalling tactics have simply made a bad situation worse. To wit: John Spangler, director of Tobacco Intervention Programs at Wake Forest University, told ABC News that Pfizer and the FDA ignored concerns...
Chances are good that if you’re a drug-industry scientist, you already know Derek Lowe’s blog In the Pipeline, which often as not focuses on the complexities of chemical synthesis and research management. Even though he works at a lab bench, Lowe also has an excellent sense of what makesĀ pharmaceutical behemoths tick from a business perspective, and offers up an insider...
Last last week, reports out of India suggested that Pfizer might make a hostile bid for generic-drug maker Ranbaxy Laboratories, which last week agreed to sell itself to Japan’s Daiichi Sankyo for roughly $4 billion. Pfizer may or may not actually try to bust up the Daiichi-Ranbaxy merger — it’s so far declined to comment. But if Pfizer does go down this path, it’ll be a...
Japanese drugmakers are anxious to expand their presence in global pharma/biotech markets where they’ve long been largely shut out — and the strong yen is making it cheaper for them to basically buy their way in. Interestingly enough, some of these deals are bypassing the U.S. altogether. Unanswered is whether these deals will come close to achieving the twin goals of reviving...
Last week, Pfizer held its promised “media roundtable” to address a rising chorus of concern about its anti-smoking drug Chantix. Reports from Pharmalot and the WSJ Health Blog suggest that Pfizer and its spokespeople offered exactly the kind of circle-the-wagons defense I’d predicted. From the WSJ blog, Pfizer’s main talking points included: Smoking is a serious health...
Moody’s has never been the most cheerful of outfits — somehow its name seems particularly fitting — and its latest missive to the drug industry is perfectly in keeping with its dour, green-eyeshade image. In short, pharmaceutical makers need to brace themselves, because their credit problems are only going to get worse, according to the rating agency. I haven’t been able...
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone
- AstraZeneca's New Blog Is Slammed by Critics
- Pfizer Aiming for 30,900 Layoffs Through 2012
- Laid-Off Merck Staff: Did You Get Your $112,000?
- Pfizer Unveils Shiny New "Leaping" Logo
- In Risperdal Kickback Case, One Nursing Home Patient Received 67 Different Drugs
- How Drug Advertising Restrictions Could Benefit the Industry
- Has Genta's Energizer Bunny of Cancer Drugs Finally Run Out of Juice?
- Amateur Hour at Merck: FDA Refuses to Look at Zetia-Lipitor Combo Pill
- AZ Promoted Seroquel as Superior to Haldol When Company Data Said It Wasn't
- The New Merck, Day 1: a Catalog of Impending Doom
- J&J Layoffs: The Jobs That Are Safest and Those That Aren't
- J&J CEO Weldon Bought $8.45M Waterfront Lot as He Planned 8,100 Layoffs
- Mylan's Halloween Scare Message: Candy May Kill Your Kids!
- Pfizer Demands DNA of Trovan Victims Who Are Owed Compensation
- Will FDA Approve MannKind's Insulin Inhaler?
- NYT's MannKind Story Needlessly Quoted a Competitor Bashing Afresa
- Microchip Implant to Link Your Health Records, Credit History, Social Security
- Hepatitis C Drugs Kill the Virus...and Your Sex Drive
- Novartis CEO Sends Emails to 140 Animal Rights Activists:
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low
- Novartis Chip Implant Texts Your Phone When You Need Another Pill
- Why Vivus's Qnexa Might Not Avoid the Obesity Drug Graveyard
Subscribe to Pharma blog comments RSS ![]()
- How NOT to Write a Biotech Press Release: Just Ask Epeius
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check
- Merck KGaA on Cancer Vaccines: We're Not Crazy, Just Convinced
- The 10 Weirdest Drug Stories of the Month
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity"
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
- Best Selling Drugs Will Soon be Biologics, But Not Owned by Biotechs
- Wyeth's Pristiq Launch is a Bust; Sales Numbers Not Noted
Industry Transcripts by Seeking Alpha
- How to choose the right insurance carrier for your business
- Real Estate: Prepare your properties to weather what lies ahead
- Technology: Be prepared if part of your global supply chain goes missing
Archives
Recommended Sources
About Pharma Industry
BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.




